Wei Wang1, Jun Ma2, Jianjun Lu2, Danqing Fang1, Xinming Xiong1, Xin Yang1, Tingting Xie3. 1. a Department of Thoracic Surgery, the Second Affiliated Hospital of Guangzhou Medical University , Guang Zhou , China. 2. b Department of Thoracic Surgery, the First Affiliated Hospital of Sun Yat-Sen University , Guangzhou , China. 3. c Department of Gastroenterology, the Second Affiliated Hospital of Guangzhou Medical University , Guang Zhou , China.
Abstract
Objective: The study aimed to investigate candidate circular RNAs (circRNAs) in regulating the pathogenic process of esophageal carcinoma. Methods: Specimens were collected from the patients with esophageal carcinoma. Total RNA was purified and treated with RNase R followed by RNA-seq in the purpose of screening the circRNAs in significant differentially expression. The expression level of the screened circRNAs were further validated using RT-PCR. The circular structure of the circRNA was validated with divergent and convergent primers. Overexpression vector was prepared in the purpose of raising the expression level of circ0043898 in the ECA-109 and Kyse-520 cells. The cell colony assay and MTS assay were conducted to determine the capacity of cell proliferation. Chamber assays were applied to determine the capacity of cell migration and invasion while flowcytometry was applied to determine the cell cycle and cell apoptosis. In vivo animal assay was conducted by injecting the cells to the chest of the mice. RNA-seq was performed followed by GO and KEGG study to further verify the regulation mechanism of circ0043898. Results: circ0043898 was validated that down-regulated expressed in the specimens from the patients with esophageal carcinoma. The cell assays proved that overexpression of circ0043898 can obviously inhibit the cell proliferation, cell migration and invasion and induce cell apoptosis and death in the cancerous cells. The in vivo animal study also suggested that the circ0043898 performed inhibitory functions on oncogenesis. The RNA-seq presented the potential regulation mechanism of circ0043898. Histone H3 and BMI1 were presented significantly differential expression in both ECA-109 and Kyse-520 cells, indicating they might be the targets of circ0043898. Conclusion: circ0043898 is presented as tumor inhibitor and could be a candidate biomarker in the therapeutic target and diagnosis of esophageal carcinoma.
Objective: The study aimed to investigate candidate circular RNAs (circRNAs) in regulating the pathogenic process of esophageal carcinoma. Methods: Specimens were collected from the patients with esophageal carcinoma. Total RNA was purified and treated with RNase R followed by RNA-seq in the purpose of screening the circRNAs in significant differentially expression. The expression level of the screened circRNAs were further validated using RT-PCR. The circular structure of the circRNA was validated with divergent and convergent primers. Overexpression vector was prepared in the purpose of raising the expression level of circ0043898 in the ECA-109 and Kyse-520 cells. The cell colony assay and MTS assay were conducted to determine the capacity of cell proliferation. Chamber assays were applied to determine the capacity of cell migration and invasion while flowcytometry was applied to determine the cell cycle and cell apoptosis. In vivo animal assay was conducted by injecting the cells to the chest of the mice. RNA-seq was performed followed by GO and KEGG study to further verify the regulation mechanism of circ0043898. Results:circ0043898 was validated that down-regulated expressed in the specimens from the patients with esophageal carcinoma. The cell assays proved that overexpression of circ0043898 can obviously inhibit the cell proliferation, cell migration and invasion and induce cell apoptosis and death in the cancerous cells. The in vivo animal study also suggested that the circ0043898 performed inhibitory functions on oncogenesis. The RNA-seq presented the potential regulation mechanism of circ0043898. Histone H3 and BMI1 were presented significantly differential expression in both ECA-109 and Kyse-520 cells, indicating they might be the targets of circ0043898. Conclusion:circ0043898 is presented as tumor inhibitor and could be a candidate biomarker in the therapeutic target and diagnosis of esophageal carcinoma.
Authors: Chung Man Chan; Kenneth K Y Lai; Enders K O Ng; Mei Na Kiang; Tiffany W H Kwok; Hector K Wang; Kwok Wah Chan; Tsz Ting Law; Daniel K Tong; Kin Tak Chan; Nikki P Lee; Simon Law Journal: Oncol Lett Date: 2017-12-27 Impact factor: 2.967
Authors: Thomas B Hansen; Erik D Wiklund; Jesper B Bramsen; Sune B Villadsen; Aaron L Statham; Susan J Clark; Jørgen Kjems Journal: EMBO J Date: 2011-09-30 Impact factor: 11.598
Authors: Leila Rouhigharabaei; Julio Finalet Ferreiro; Natalie Put; Lucienne Michaux; Thomas Tousseyn; Christine Lefebvre; Anne Gardiner; Wim De Kelver; Hilde Demuynck; Johan Verschuere; Ivan Théate; Carmen Vicente; Peter Vandenberghe; Jan Cools; Iwona Wlodarska Journal: Genes Chromosomes Cancer Date: 2013-07-19 Impact factor: 5.006
Authors: Yu Qi; Ke Xin Cao; Fu Chen Xing; Chun Yang Zhang; Qi Huang; Kai Wu; Feng Biao Wen; Song Zhao; Xin Li Journal: Oncol Lett Date: 2017-07-20 Impact factor: 2.967
Authors: Jie Li; Qiang Xu; Zi-Jian Huang; Ning Mao; Zhi-Tao Lin; Long Cheng; Bei Sun; Gang Wang Journal: Cell Death Dis Date: 2021-02-24 Impact factor: 8.469